# Beijing Anzhen Hospital: Not applicable (device, behavioral) study in Atrial Fibrillation (AF), Ablation Treatment (700 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Beijing Anzhen Hospital |
| Sponsor type | Academic and hospital |
| Study | Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients |
| NCT ID | NCT07897305 |
| Phase | Not applicable (device, behavioral) |
| Status | not yet recruiting |
| Conditions | Atrial Fibrillation (AF); Ablation Treatment; Obesity & Overweight; Mazdutide |
| Intervention types | drug, other |
| Target enrollment | 700 |
| Site countries | China |
| Posted | 2026-10-27 |
| Planned start | 2026-10-25 |
| Event | Newly registered study |
| Event date | 2026-10-27 |

## Why this score
- Posted in the last two weeks.
- 700 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07897305). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.